VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods. 

Biotechnology

VantAI

Zachary Carpenter

Michael Bronstein

Kelly Velez

Natasha Zaliznyak

Si-Han Chen

Luca Naef

The leadership team at VantAI has a wide range of experience in many different industries. Many of them have worked in the pharmaceutical industry, as well as in medical sales and research. They have also taught at various universities. Their education histories are also quite varied, with degrees in biomedical sciences, bioinformatics, organic chemistry, pharmaceutical sciences, chemical and biomolecular engineering, information management, and chemical biology.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at VantAI

Board of Directors

CEO and Executive Team